Anagrelide (Agrylin): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

What Is Anagrelide?

Anagrelide is a platelet-reducing, or cytoreductive, medication. It is approved in the United States for thrombocythemia associated with myeloproliferative neoplasms. Its goals are to lower an elevated platelet count, reduce the risk of blood clots, and improve symptoms related to abnormal clotting or bleeding.

Platelets are tiny blood cells that help seal damaged blood vessels. Think of them as the body’s emergency patching crew. Too few platelets can lead to bleeding, but far too many can contribute to dangerous clots. Anagrelide helps bring an overenthusiastic platelet department back under control.

Conditions treated with anagrelide

Anagrelide may be prescribed for thrombocythemia caused by conditions such as:

• Essential thrombocythemia, also called essential thrombocytosis
• Polycythemia vera with an elevated platelet count
• Other myeloproliferative neoplasms that cause excessive platelet production

It may be considered when platelet-lowering treatment is necessary and another therapy is unsuitable, ineffective, or poorly tolerated. Treatment choice depends on age, clotting history, pregnancy plans, cardiovascular health, genetic findings, symptoms, and the specific myeloproliferative neoplasm. Anagrelide controls platelet production but does not cure the underlying bone marrow disorder.

How Does Anagrelide Work?

Platelets develop from large bone marrow cells called megakaryocytes. Anagrelide disrupts the later stages of megakaryocyte development, reducing their size and ability to produce platelets. At typical therapeutic doses, it generally has less direct effect on white blood cell production than some other cytoreductive drugs.

Anagrelide and its active metabolite also inhibit phosphodiesterase 3, usually shortened to PDE3. This activity helps explain several cardiovascular effects, including a faster heartbeat, palpitations, widening of blood vessels, and, in susceptible patients, worsening heart failure. In other words, the same medication that tells platelets to calm down may tell the heart to pick up the tempo.

Anagrelide Dosing

Anagrelide dosing must be individualized according to platelet counts, side effects, liver function, and cardiovascular risk. The following information reflects U.S. prescribing guidance, not a personal dosing recommendation.

Recommended adult starting dose

The labeled starting dosage for adults is either:

• 0.5 mg four times daily, or
• 1 mg twice daily

The starting dosage should generally be continued for at least one week. The prescriber may then adjust the total daily dose according to platelet response and tolerability.

Dose increases and maximum dose

The total daily dosage should not be increased by more than 0.5 mg during any one-week period. The labeled maximum is 10 mg per day, with no more than 2.5 mg taken as a single dose. Most responding patients in clinical studies required a total daily dosage between 1.5 and 3 mg.

The treatment target is usually a platelet count below 600,000 per microliter, with an ideal range of approximately 150,000 to 400,000 per microliter. The precise goal may differ according to the patient’s diagnosis and clinical risks.

Pediatric dosing

For pediatric patients age 7 years and older, the labeled starting dosage is 0.5 mg once daily. Pediatric treatment should be managed by a specialist familiar with childhood myeloproliferative disorders. Safety and effectiveness have not been established for children younger than 7.

Dosing with liver impairment

For moderate hepatic impairment, defined in the label as a Child-Pugh score of 7 to 9, the recommended starting dosage is 0.5 mg once daily. If the medication is tolerated for one week, increases may be considered, but they should not exceed 0.5 mg per day in any one week.

Anagrelide exposure can rise substantially when liver function is impaired. Use should be avoided in severe hepatic impairment, and patients with mild or moderate impairment require careful cardiovascular and laboratory monitoring.

How to Take Anagrelide Safely

• Take each dose at approximately the same time every day.
• Anagrelide may be taken with or without food.
• Follow the exact schedule printed on the prescription label.
• Do not take additional capsules because a platelet count still looks high.
• Do not stop treatment suddenly unless a healthcare professional directs you to do so.

Platelet counts commonly begin responding within 7 to 14 days after an effective dose is reached. A complete response in clinical studies often took 4 to 12 weeks. This delay is why increasing the dose too quickly is riskythe medication may be working before the latest blood test has finished telling the story.

Required blood tests and monitoring

The prescribing information recommends checking platelet counts every two days during the first week of treatment and at least weekly afterward until a maintenance dosage is reached. During stable long-term therapy, testing may become monthly or follow another schedule chosen by the treating clinician.

Monitoring may also include a complete blood count, liver tests, kidney function, electrolytes, blood pressure, heart rate, and electrocardiograms. If treatment is interrupted, platelets may begin rising within four days and can return to baseline within one to two weeks, sometimes rebounding above the original count.

What if you miss a dose?

Take the missed dose when you remember unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and return to the regular schedule. Do not take two doses together to catch up.

Common Anagrelide Side Effects

Side effects tend to be most noticeable when treatment begins or after a dosage increase. Some improve as the body adjusts or after the prescriber changes the dose or divides it differently throughout the day.

Frequently reported anagrelide side effects include:

• Headache
• Palpitations or awareness of the heartbeat
• Diarrhea
• Weakness or low energy
• Swelling or fluid retention
• Nausea, gas, indigestion, or abdominal discomfort
• Dizziness
• Fast heartbeat
• Reduced appetite
• Vomiting
• Shortness of breath or cough
• Rash or itching
• Back, muscle, or joint pain

In clinical studies involving 942 patients with myeloproliferative neoplasms, headache was reported in 44%, while palpitations and diarrhea were each reported in 26%. Weakness, edema, nausea, abdominal pain, and dizziness were also common. Trial percentages describe groups of patients; they cannot predict exactly what one person will experience.

Ways to manage mild side effects

Patients should discuss bothersome symptoms rather than quietly declaring war on them at home. Depending on the problem, a clinician may recommend taking doses with food, dividing the daily dosage differently, increasing more slowly, checking blood pressure, replacing low electrolytes, or evaluating another cause. Persistent diarrhea, vomiting, or reduced appetite can lead to dehydration and should not be ignored.

Serious Side Effects and Emergency Warning Signs

Seek immediate medical attention for severe chest pain, fainting, a sustained irregular heartbeat, sudden weakness on one side, trouble speaking, severe shortness of breath, coughing or vomiting blood, black stools, or uncontrolled bleeding.

Heart rhythm and cardiovascular problems

Anagrelide can increase heart rate and prolong the QT interval, an electrical measurement on an ECG. Torsades de pointes, ventricular tachycardia, heart failure, cardiomyopathy, atrial fibrillation, and other serious cardiovascular events have been reported.

A cardiovascular examination, including an ECG, is recommended before treatment. Additional ECG monitoring may be needed for patients with heart failure, slow heart rhythms, electrolyte abnormalities, liver impairment, or other cardiac risk factors.

Pulmonary hypertension and lung injury

Pulmonary hypertension, which is high pressure in the blood vessels supplying the lungs, has occurred during anagrelide treatment. Warning signs include worsening shortness of breath, chest discomfort, faintness, ankle swelling, or bluish lips and skin.

Rare cases of interstitial lung disease have also been reported. These conditions may begin after only a week or after several years of treatment. Progressive breathlessness, a persistent dry cough, fever, or abnormal lung imaging requires prompt evaluation.

Bleeding

Anagrelide may increase bleeding risk, particularly when combined with aspirin or another medicine that affects clotting. Warning signs include unusual bruising, frequent nosebleeds, blood in urine, red or black stools, vomiting blood, prolonged bleeding from small cuts, or unusually heavy menstrual bleeding.

Other rare but serious reactions

Postmarketing reports have included clinically significant liver injury, tubulointerstitial nephritis, severe thrombocytopenia, cerebral infarction, serious allergic reactions, and kidney failure. Contact a healthcare professional promptly for yellowing of the eyes, dark urine, markedly reduced urination, facial swelling, hives, or worsening fatigue accompanied by abnormal laboratory results.

Important Anagrelide Warnings

QT prolongation

Anagrelide should not be used in people with major risk factors for QT prolongation, such as congenital long QT syndrome, known acquired QT prolongation, untreated low potassium, or concurrent use of certain QT-prolonging medicines. Correcting low potassium or magnesium may be necessary before treatment.

Existing heart disease

People with heart failure, coronary disease, rhythm disorders, or other cardiovascular conditions require an individualized risk-benefit assessment. The official label states that anagrelide should be used in patients with cardiac disease only when its anticipated benefits outweigh the risks.

No formal contraindications does not mean no risk

The U.S. label lists no formal contraindications. That does not translate to “safe for absolutely everyone.” It is still advised to avoid the medicine in severe liver impairment and in patients with specific QT-related risk factors. Medical labels can be oddly literal creatures, so the warnings section matters just as much as the contraindications box.

Anagrelide Drug Interactions

Give the prescriber and pharmacist a complete list of prescription drugs, over-the-counter medicines, vitamins, and herbal products. Important interaction groups include the following.

Medicines that prolong the QT interval

Combining anagrelide with another QT-prolonging medicine can increase the risk of a dangerous abnormal heart rhythm. Examples named in U.S. prescribing information include clarithromycin, moxifloxacin, methadone, haloperidol, chloroquine, amiodarone, disopyramide, procainamide, and pimozide.

Other PDE3 inhibitors

Avoid combining anagrelide with drugs that have similar PDE3-inhibiting effects, including cilostazol and milrinone, unless a specialist has specifically evaluated the combination. Cardiovascular effects may become more pronounced.

Aspirin, anticoagulants, and other bleeding-risk medicines

Aspirin is sometimes intentionally prescribed for people with essential thrombocythemia, but it should not be added independently. Anagrelide plus aspirin has been associated with increased major bleeding in some patients.

Additional medicines that may increase bleeding include warfarin, apixaban, rivaroxaban, dabigatran, heparin, clopidogrel, ibuprofen, naproxen, other NSAIDs, and selective serotonin reuptake inhibitor antidepressants. Even if two drugs do not alter each other’s blood concentration, their effects on bleeding can still add up.

CYP1A2 interactions

Anagrelide is primarily metabolized by the CYP1A2 enzyme. CYP1A2 inhibitors such as fluvoxamine and ciprofloxacin may increase anagrelide exposure and cardiovascular side effects. CYP1A2 inducers may reduce exposure and effectiveness. The label names omeprazole as an example that may require dose reassessment.

Anagrelide may also alter exposure to certain CYP1A2 substrates, including theophylline, ondansetron, and fluvoxamine. Never assume that a familiar antibiotic, stomach remedy, or antidepressant is automatically compatible.

Pregnancy, Breastfeeding, Fertility, and Special Populations

Pregnancy

Human pregnancy data are limited. Available case reports have not established a clear drug-associated risk of major birth defects or miscarriage, but that does not prove the medication is risk-free. Thrombocythemia itself can increase the risk of blood clots, miscarriage, stillbirth, and preeclampsia, making pregnancy management particularly complex.

Anyone who is pregnant, could become pregnant, or is planning pregnancy should consult both a hematologist and an obstetric specialist before starting, continuing, or stopping treatment.

Breastfeeding and fertility

Breastfeeding is not recommended during anagrelide treatment or for one week after the final dose because of the possibility of serious reactions, including low platelet counts, in a nursing infant. Animal studies also suggest that anagrelide may impair female fertility.

Older adults

Older adults may have greater exposure to anagrelide and may be more sensitive to cardiovascular, blood-pressure, and fluid-retention effects. Age alone does not prohibit treatment, but careful titration and monitoring are important.

Kidney impairment

A single-dose pharmacokinetic study did not find a major change in anagrelide exposure in severe renal impairment. However, kidney function is still monitored because renal failure and inflammatory kidney injury have been reported. A patient’s broader medical condition may influence the dosing decision.

Anagrelide Pictures and Capsule Identification

Anagrelide is supplied as an oral capsule, but its appearance depends on the manufacturer and strength. Pill color alone is not a reliable identification method.

• Brand-name Agrylin 0.5 mg: The U.S. brand labeling describes a white, opaque capsule with “063” printed in black.
• One generic 0.5 mg product: A gray cap and white body marked “1453” and “0.5 mg.”
• One generic 1 mg product: A white cap and white body marked “1462” and “1 mg.”

Other generic versions may have different colors, sizes, and imprint codes. Compare the capsule with the pharmacy label and manufacturer information. If a refill suddenly looks different, ask the pharmacist before taking it. Do not rely solely on an online photograph, especially when several medications have similar capsule wardrobes.

Overdose and Storage

An overdose can cause an excessive drop in platelet count, bleeding, low blood pressure, vomiting, or a rapid heartbeat. Suspected overdose requires immediate professional guidance. In the United States, contact Poison Control at 1-800-222-1222; call 911 for collapse, severe breathing difficulty, heavy bleeding, seizures, or loss of consciousness.

Store anagrelide at controlled room temperature, generally 68°F to 77°F, in a tightly closed, light-resistant container. Keep it away from excessive moisture, heat, children, and pets. A bathroom medicine cabinet is convenient, but steam does not make a good roommate for medication.

Practical Experiences During Anagrelide Treatment

The following discussion describes common treatment patterns and practical challenges rather than the experience of one specific patient. Responses vary substantially, and some people tolerate anagrelide much better than others.

The first few weeks can feel busy

Beginning anagrelide often involves more appointments and laboratory tests than patients expect. Blood may be drawn every few days, the medication schedule may include several daily doses, and the first prescription may not be the final dose. This is deliberate. The goal is to find the lowest effective dosage without sending the platelet count too far in the opposite direction.

Headaches, palpitations, stomach upset, loose stools, dizziness, and fatigue may be most noticeable during this adjustment period. A patient may feel perfectly normal before taking the medication and wonder why treatment has made the heartbeat suddenly impossible to ignore. Reporting these effects early allows the healthcare team to check heart rhythm, blood pressure, hydration, electrolytes, and the pace of dose escalation.

A medication routine becomes valuable

When a medicine is taken two to four times daily, memory alone is an unreliable personal assistant. A pill organizer, phone alarm, printed schedule, or medication-tracking app can reduce missed and duplicated doses. Some patients connect each dose with a regular activity, such as breakfast, lunch, dinner, and bedtime, while still following the exact prescribed intervals.

Taking the capsule with a small meal may help nausea or stomach discomfort, although it can be taken without food. Patients who experience dizziness may find it useful to stand slowly, remain well hydrated, and avoid driving until they know how the medication affects them.

Laboratory improvement may arrive before symptom improvement

The platelet count may start falling within one or two weeks, but reaching a stable target can take longer. Some symptoms associated with thrombocythemiasuch as headaches, visual disturbances, tingling, or burning discomfort in the hands and feetmay improve as the count comes under control. Other symptoms may have a different cause and may not disappear simply because the laboratory number looks better.

This distinction matters. Successful treatment is not just a prettier number on a blood test. Clinicians also consider clotting events, bleeding, medication tolerability, quality of life, and signs that the underlying myeloproliferative neoplasm is changing.

Keeping a brief symptom diary can help

A simple daily record can make follow-up visits more productive. Useful details include dose times, headache severity, bowel changes, resting pulse, dizziness, swelling, unusual bruising, shortness of breath, and any newly started medication. The diary does not need to become a 400-page epic. A few accurate lines are more useful than trying to reconstruct three weeks of symptoms in the waiting room.

Communication prevents avoidable problems

One of the most important practical lessons is to check before adding common medicines. A patient may reasonably assume that aspirin, ibuprofen, naproxen, an antibiotic, or an over-the-counter stomach remedy is harmless. With anagrelide, these products may increase bleeding, affect heart rhythm, or change drug exposure.

Patients should also tell dentists, surgeons, urgent-care clinicians, and pharmacists that they take anagrelide. This becomes especially important before procedures or when a new prescription is being considered.

Stopping suddenly can create a different risk

When side effects become frustrating, skipping treatment may feel like the fastest solution. However, platelet counts can begin rising within days after anagrelide is stopped. The safer approach is to contact the hematology team, which may adjust the dosage, change dose timing, pause treatment with laboratory monitoring, or recommend another therapy.

Long-term treatment can require patience, but a workable plan should not demand silent suffering. Persistent palpitations, significant swelling, progressive breathlessness, recurrent bleeding, or intolerable gastrointestinal symptoms deserve reassessment rather than a heroic attempt to “push through.”

Conclusion

Anagrelide can effectively reduce excessive platelet production in essential thrombocythemia and other myeloproliferative neoplasms. Its benefits, however, come with a need for careful dose titration, frequent platelet testing, cardiovascular assessment, and a thorough review of drug interactions.

Common problems such as headaches, diarrhea, palpitations, dizziness, and swelling may be manageable, but chest pain, irregular heartbeat, fainting, major bleeding, or worsening shortness of breath requires prompt medical attention. The best anagrelide regimen is not the highest dose or the fastest dose increaseit is the lowest well-tolerated dose that safely controls the platelet count.